以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 ▍肥胖药物治疗需科学规范 肥胖已发展为全球突出的公共健康难题，我国超重及肥胖人数已逾6亿。《减肥药物临床实践医药专家共识》围绕药物疗效、安全性及个体化方 案，首次全面梳理并发布24条专业建议，为临床从药物选择到特殊人群管理提供全方位路径。共识指出，药物治疗应基于生活方式调整，构 建"生活干预+药物"为支撑的综合管理体系。 ▍药物治疗与生活方式干预的协同 1. 科学设定药物减重目标 疗效显著：临床证据显示，规范应用减重药物可带来5%-15%的体重下降，GLP-1类药物（如司美格鲁肽、替尔泊肽）在III期研究中帮助肥胖 患者减重15%-20.9%，同时改善血糖、血脂等多项代谢指标（见推荐1、13）。 减重目标全面升级：不仅关注体重下降数值，更强调长期体重维持、并发症缓解（如心血管事件风险降低20%）及生活质量提升，部分药物 （如替尔泊肽）更被证实可逆转非酒精性脂肪性肝炎（见推荐4、10）。 2. 生活方式干预为减重基石： 共识指出，饮食调整（如低碳水饮食） ...

整理 | GLP1减重宝典内容团队 近年来，司美格鲁肽凭借强劲的发展势头，迅速崛起为代谢类药物领域的明星产品，距离成为"全球药王"仅一步之遥。诺和诺德公司2024年的 财报显示，司美格鲁肽全系产品在2024年全年实现收入2018.49亿丹麦克朗（约合292.96亿美元），仅以微弱劣势不敌K药。然而， 考虑到司美 格鲁肽正处于高速增长阶段，而K药的增长已逐渐放缓，2025年司美格鲁肽有望登上"全球药王"的宝座 。 不过，司美格鲁肽能否在"全球药王"的位置上长期停留，仍存在不确定性。 未来一段时间内，来自中国的众多司美格鲁肽生物类似药可能会成 为影响市场走向的重要因素。 诺和诺德司美格鲁肽的专利将于2026年到期。 2025年3月31日，华东医药公告称，司美格鲁肽注射液的上市许可申请正式获受理，申报适应症为成人2型糖尿病患者的血糖控制。 2020年10月，中美华东与参股公司重庆派金生物科技有限公司签署合作协议，共同开发及商业化司美格鲁肽注射液。重庆派金负责完成临床前 研究，达到申报中国临床试验申请（IND）的标准；中美华东则负责后续的全球开发、注册及商业化工作。 2022年6月，华东医药的司美格鲁肽注射液2型糖尿 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 ▍体重稳定更长寿 体重的变化反映了一个人的生活方式，能够做到体重稳定的人，通常饮食均衡、运动规律，睡眠和心态也较为健康，而这些正是长寿的重要因 素。 加州大学圣地亚哥分校的科学家们，专门研究了老年女性在短期（3年）和长期（10年）内的体重变化，与她们活到90岁、95岁甚至100岁的概 率之间的关系。 研究共纳入了54437名年龄在61至81岁的女性，分别在研究初期、第3年和第10年测量她们的体重。 根据体重变化，研究人员将参与者分为三组： 1.体重减少（比基线降低≥5%）； 2.体重增加（比基线上升≥5%）； 3.体重基本稳定（比基线变化<5%）。 最终数据显示，有30647名女性（占总人数的56%）至少活到了90岁。 进一步分析发现，体重保持稳定的女性，活到90岁及以上的概率更高。 与体重减少5%或以上的女性相比，体重稳定者长寿的可能性高出1.2到2倍。体重减少≥5%的女性，活到90岁、95岁和100岁的概率较低；而体 重增加≥5%的人，与长寿几乎没 ...

Core Viewpoint - The article discusses the rising trend of weight loss among celebrities and public figures, highlighting the role of GLP-1 medications like Semaglutide and Tirzepatide in achieving significant weight loss results, with average reductions of 15% and 20% respectively. The impact of social media on public perception and awareness of weight loss is also emphasized [3][20][26]. Group 1: Celebrity Weight Loss Stories - Chinese singer and actress Chui Nalisah lost 70 pounds due to health concerns, specifically severe fatty liver disease, and emphasizes the importance of health over aesthetics [3][7]. - Elon Musk reported a weight loss of 30 pounds (approximately 27.2 pounds) using Semaglutide [8]. - Oscar winner Whoopi Goldberg shared her experience of using Tirzepatide to manage her weight after gaining due to steroid treatment [10]. - Grammy winner Kelly Clarkson attributed her slim figure to Semaglutide, alongside a high-protein diet and exercise [12]. - Jon Gosselin lost 32 pounds in two months after using Semaglutide, expressing regret for not starting earlier [14]. - Jeremy Clarkson began using Semaglutide after hearing positive feedback from others about its appetite-suppressing effects [16]. - Influencer Shannon Natalia lost approximately 20 kilograms with the help of Semaglutide while battling lipedema [18]. Group 2: Efficacy of Semaglutide - The STEP series of studies demonstrated that Semaglutide leads to an average weight loss of 15% in obese patients, significantly outperforming previous weight loss medications [20][25]. - In the STEP 1 study, participants lost an average of 14.9%, with over one-third losing more than 20% of their body weight [22]. - The STEP 2 study showed a 10.6% average weight reduction in patients with type 2 diabetes, with improvements in cardiovascular risk factors and quality of life [22]. - The STEP 3 study indicated a 16% weight loss when combined with behavioral therapy, compared to 5.7% in the placebo group [22]. - The STEP 4 study found that continuous use of Semaglutide resulted in an 18.2% weight loss over time [23]. - The STEP 7 study, focusing on a Chinese population, reported a 12.1% average weight loss with Semaglutide [23]. Group 3: Efficacy of Tirzepatide - The SURMOUNT-1 study showed that Tirzepatide significantly reduced weight in prediabetic patients, with average weight losses of 15.4% to 22.9% depending on dosage [26][28]. - The SURMOUNT-2 study confirmed a 15.7% average weight loss in type 2 diabetes patients using higher doses of Tirzepatide [28]. - The SURMOUNT-3 trial reported a weight loss of up to 26.6% after 72 weeks of treatment [30]. - The SURMOUNT-5 trial indicated that Tirzepatide outperformed Semaglutide, with participants losing an average of 50.3 pounds (22.8 kg) compared to 33.1 pounds (15.0 kg) for Semaglutide [30].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 近日，"国家喊你减肥"这一话题持续升温，"体重管理"理念正悄然走入高校，并迅速引发热潮。各大高校也在推动"体重管理"方面下足了功 夫，从饮食管控到锻炼指导，纷纷推出多项举措，助力大学生健康减重，积极培养良好的生活习惯。 在北京大学，《体能提升：运动与膳食》成为最受欢迎的体育课程之一。为何体育课要花心思教大家如何饮食？主讲老师张晓圆是运动营养学 专家，她认为，减重不仅要多运动，还要注重饮食控制，做到摄入的热量少于消耗的热量。张老师会为每位同学量身定制膳食计划，并带学生 走进食堂，手把手教大家如何科学搭配，既能控制热量，又能吃得饱、有营养。 ▍北科大推出复刻版卫健委食谱"减脂套餐" 每到用餐时间，北京科技大学食堂的这个小窗口前总是排满了等待的学生，大家都在抢购新推出的减脂餐。紫米饭、带鱼、绿豆芽，再加上一 碗酸奶，搭配虽简单，却备受欢迎。这款减脂套餐正是学校食堂根据国家卫健委2024年新版《成人肥胖食养指南》专门研发推出的健康选择。 北京科技大学后勤管理处 ...

整理 | GLP1减重宝典内容团队 食物约占每日总水摄入量的 20%，这意味着，如果使用 GLP-1，减少进食量可能会面临脱水风险，尤其是如果饮水量也下降的话。 来自一项 针对大鼠的研究 证据表明，减肥药除了抑制食欲外，实际上还可以抑制水的摄入量。 适当补水不仅能保持体内水分平衡，还能帮助创造更好的环境，让药物发挥最佳作用。因此，补水充足不仅能减轻副作用，还能增强药物的疗 效。 水对身体的几乎所有功能都至关重要，但在积极尝试减肥时，水的作用尤其重要。如果我们喝的水不足，我们的身体就难以发挥最佳功能，从 而导致减肥过程中出现潜在障碍。以下是保持水分充足的关键原因： 补水对消化和药物代谢至关重要 补水会影响所有人的消化过程的每个部分，良好的补水很重要，可以确保有足够量的消化液（如唾液、胃酸、酶）来帮助食物通过并开始分解 食物的过程。一旦食物分解，水就会帮助将水溶性维生素、矿物质和其他营养物质输送到全身，最后，在大肠中，需要水来使粪便更软，更容 易排出。喝水不足会导致便秘，粪便在大肠中停留的时间越长，产生胀气和腹胀的机会就越多，也会看起来会更胖。 多喝水能帮助药物在胃肠道的溶解与吸收，让药物分布均匀，减少对胃肠道的 ...

Core Viewpoint - Obesity has become a global health challenge, with significant advancements in the development of anti-obesity drugs, with over 100 new treatments in development aimed at providing safer and more effective weight loss options for patients [1] Group 1: Upcoming Drug Approvals - Orforglipron from Eli Lilly is expected to be approved in 2026 as an oral small-molecule drug activating the GLP-1 receptor [2] - CagriSema from Novo Nordisk, also expected in 2026, is an injectable that activates both amylin and GLP-1 receptors [2] - Survodutide from Boehringer Ingelheim and Retatrutide from Eli Lilly are anticipated in 2027, both being injectables that activate multiple receptors [3] - MariTide from Amgen and Bimagrumab from Eli Lilly are projected for approval in 2028 and beyond, with unique mechanisms targeting GLP-1 and myostatin signaling respectively [3] Group 2: Mechanisms and Efficacy - New generation drugs are focusing on protecting muscle quality while promoting weight loss, addressing the limitations of traditional drugs like semaglutide, which can lead to muscle loss [4] - Dual-action drugs like tirzepatide, which mimics both GLP-1 and GIP, have shown superior weight loss results, with participants losing an average of 20% of their body weight [5] - CagriSema has demonstrated an average weight loss of nearly 23% in a 68-week Phase III trial [9] Group 3: Delivery Methods and Patient Compliance - The industry is exploring more convenient delivery methods, including monthly injections and oral medications, to improve patient compliance [13] - Orforglipron is expected to be the first oral anti-obesity drug, with a 15% weight loss observed in a 36-week Phase II study [13] Group 4: Genetic Insights and New Targets - Advances in genetic sequencing have identified new targets for obesity treatment, with companies like Alnylam Pharmaceuticals developing therapies based on gene mutations associated with lower body weight [14][17] - The potential of next-generation CB1 antagonists is being explored, aiming to avoid severe side effects while improving metabolic outcomes [18] Group 5: Muscle Preservation - Muscle preservation is becoming a key focus in obesity treatment, with existing GLP-1 drugs potentially leading to muscle loss [19] - Bimagrumab, a monoclonal antibody targeting myostatin, has shown promise in reducing muscle loss while promoting fat breakdown, with a 22% reduction in fat mass observed in a 48-week trial [20][22] - The development of muscle-targeting therapies is still in early stages but is gaining attention as a crucial component of future obesity treatment strategies [25]

Core Viewpoint - The article emphasizes the urgent need for effective weight management and obesity prevention strategies in China, highlighting the significant health, psychological, and economic burdens associated with obesity [6][7]. Group 1: Obesity Burden in China - In 2020, the overweight rate among adults aged 18 and above in China reached 34.3%, with an obesity rate of 16.4% [9] - By 2021, the number of overweight and obese individuals aged 25 and above had increased to 402 million, making China the country with the highest prevalence globally [9] - Projections indicate that by 2030, the adult overweight and obesity rate could rise to 70.5%, with school-aged children reaching 31.8% and preschool children at 15.6% [9] Group 2: Health Risks Associated with Obesity - Obesity significantly increases the risk of over 200 diseases, including diabetes, stroke, and heart disease, with 90% of obese individuals suffering from at least one comorbidity [12] - The risk of hypertension is 2.5 times higher for overweight individuals and 3.3 times for obese individuals compared to those with normal weight [12] - Obesity also negatively impacts reproductive health and increases the risk of complications during pregnancy [12] Group 3: Psychological and Social Impacts - Individuals with obesity often face social stigma and discrimination, particularly among children, adolescents, and women [13] - There is a strong correlation between obesity and mental health issues such as depression and anxiety [13] - Obesity can lead to decreased quality of life and reduced work productivity [13] Group 4: Economic Burden of Obesity - By 2030, annual medical costs associated with overweight and obesity in China are projected to reach 418 billion RMB, accounting for 22% of national healthcare expenditures [14] - Obesity increases hospitalization rates and healthcare resource consumption, placing additional economic pressure on individuals and families [14] Group 5: Risk Factors for Obesity - Key risk factors for obesity include unhealthy dietary habits, lack of physical activity, and genetic predisposition [15] - For children, significant risk factors include maternal pre-pregnancy weight, short breastfeeding duration, and excessive screen time [15] Group 6: Prevention Strategies - Establishing supportive environments for health, such as community fitness facilities and healthy dining options, is crucial [16] - Public education on the dangers of obesity and healthy weight management should be prioritized [16] - Encouraging regular physical activity and healthy eating habits is essential for obesity prevention [16] Group 7: Treatment and Management of Obesity - Lifestyle interventions, including dietary changes and increased physical activity, are the primary treatment methods for obesity [19] - For individuals with severe obesity or metabolic complications, pharmacological treatments and surgical options may be considered [19] - A multidisciplinary approach involving nutritionists, exercise specialists, and medical professionals is recommended for comprehensive obesity management [19]

整理 | GLP1减重宝典内容团队 埃隆·马斯克 (Elon Musk) 在从 Ozempic 升级为被称为"金刚"的减肥药Mounjaro的药物后，体重有所减轻。 53 岁的马斯克在其社交媒体平台 X 上的一篇节日帖子中承认转用 Mounjaro。 马斯克之前一直在服用 Ozempic， 他声称 "Mounjaro 的副作用似乎更少"，而且似乎"更有效" 。 Mounjaro是近年来越来越受欢迎的众多减肥药之一，目前由诊所和药房私下销售。 Mounjaro 于今年3月开始在英国国民医疗服务体系（NHS）也即英国公费医保体系逐步推出。 NHS 制定了一项长期计划，旨在让 Mounjaro 广泛普及。然而，这需要时间， 可能长达12 年才能确保能够满足所有患者的需求 ，由于担心该药物可能使NHS不堪重负，以及为了测试提供 新一代减肥药物的方法。从今年 3 月起，将通过体重管理服务向医疗需求最高的人提供此注射剂，即那些 至少有三种肥胖相关健康问题的人 。根据英国国家卫生与服务优化研究院（NICE）指南，该指南规定 Mounjaro 将通过NHS提供给 BMI 超过 35 且至少有一种肥胖相关健康问题 的人。 BB ...

整理 | GLP1减重宝典内容团队 最新研究显示，用于糖尿病和体重控制的药物——特别是胰高糖素样肽-1（GLP-1）受体激动剂——可能在治疗银屑病方面发挥作用。这是一 种慢性自身免疫性皮肤疾病，由于皮肤细胞生长过快，会导致皮肤出现红色、鳞屑状和发炎的斑块。科学家正探索这类具有抗炎特性的GLP-1 药物是否也能帮助缓解银屑病。 不过，二者之间的联系并不简单。美国皮肤病学会（AAD）年会上一项研究指出，尽管GLP-1药物似乎能降低银屑病患者的炎症水平，但这并 未显著改善患者的皮肤症状或生活质量。因此，GLP-1药物究竟是银屑病治疗的突破口，还是尚在验证的新尝试？ GLP-1药物在银屑病中的潜在作用 在AAD大会上，来自巴西的研究人员发布了一项荟萃分析结果，纳入了6项研究，共85名同时患有银屑病及糖尿病或肥胖的参与者。其中63人 接受了GLP-1药物治疗，疗程为8到20周不等。 研究人员指出，治疗后参与者体内的C反应蛋白（CRP）和肿瘤坏死因子α（TNF-α）水平有所下降，表明炎症有所缓解。TNF-α是一种引发炎 症反应的分子，在银屑病的发生中起重要作用。"一些用于治疗银屑病的生物制剂就是通过阻断TNF-α起效的， ...